The method of treatment of acute respiratory infections in young farm animals

 

(57) Abstract:

Usage: in veterinary medicine, namely for the treatment of acute respiratory diseases in farm animals. The invention consists in the fact that calves administered for 5 to 7 days glycomics dose of 10 to 20 cm3on 1 pet. The treatments are more effective when combined (intravenous, intramuscular) parenteral administration of glucovance with Autocraft.

The invention relates to veterinary pharmacology, in particular to methods of treatment of acute respiratory infections in young farm animals. Good effect in acute respiratory diseases is achieved by an integrated treatment on the background of the optimum conditions of feeding and maintenance.

Known methods of treatment of acute respiratory infections in young farm animals, comprising injecting into the animal organism preparations containing antibiotics, such as streptomycin, erythromycin or bicillin-3 and the solvent carrier (for example, 0.5% solution of novocaine), 1-2 times a day, to recover (see A. J. Laborers. Treatment and prevention of non-communicable diseases on dairy farms. L. Kolos, 1980, S. tibiotic, led to the development of the microflora stability and, consequently, reduce their therapeutic efficacy. For demonstration of therapeutic action often takes two introduction into the organism of animals used drugs (double course of treatment), which leads to higher vertical treatment of sick animals. In addition, the constant increase in the cost of drugs in recent times, not only leads to a limitation of their use, and in some cases and to refuse treatment and, as a result, the forced slaughter of animals.

There are also known methods of treatment of acute respiratory diseases in calves, comprising injecting into the body of the animal until recovery of a medicinal product containing as a chemotherapeutic antibiotic, such as norfolkline or holomorphically, glucose and the solvent water [1] the Disadvantages of the same.

The aim of the invention is to increase the efficiency of the method of treatment of acute respiratory infections, mainly pneumonia in calves and reduce the cost of ongoing veterinary activities in this disease.

The purpose of shortcuts is as a solvent saline solution in the following ratio of components, wt. Dioxidine 0,45-0,55 Glucose 5,00-40,00 saline Else which is injected in the animals once a day at a dose of 10-20 cm3. When combined parenteral drug intravenously, intramuscularly dose of the drug, administered intravenously, is reduced by 20-25% and the dose, injected intramuscularly, fill to the original volume by Autocraft.

Dioxidine is a chemotherapeutic agent with a wide spectrum of activity used in the treatment of severe purulent-inflammatory processes: pleuritis, empyema, peritonitis, cystitis, wounds with deep purulent cavities (see M. A. Klyuev, Medicines used in medical practice in the USSR. The Handbook. M. Medicine, 1989, S. 118).

The invention is illustrated by the following examples.

P R I m e R 1. The drug, used to treat pneumonia of calves, prepared by dissolving the calculated amount of physiological solution first, glucose, then dioksidina. The finished drug is dispensed in ampoules of 10-20 cm3or vials of neutral glass with a volume of 50, 100, 200 or 400 cm3; sealed ampoules, vials closed with rubber stoppers, sealcoat and sterilized. Prepay m m e R 2. In fattening complex for growing steers treatment 50 calves from 20 to 45 days of age (1 experimental group) and 55 calves from 45 to 90 days of age (2 experimental group), patients with bronchopneumonia. The keeping of animals in the complex on a concrete slab floors. In calves celebrate weakness, loss of appetite, temperature ranges 41,0-41,5aboutwith symptoms of rhinitis, bronchitis, cough, watery eyes. For the treatment of drug use "Glycomics", containing the following components, wt. Dioxidine 0,45 Glucose 40,00 saline Rest of the Drug is administered intravenously, once a day until recovery, the animals I experienced groups in the dose of 10 cm3animals 2 the experimental group at a dose of 20 cm3.

The control group of animals of the same age groups (60 and 65 goal) is treated by intramuscular injection of antibiotics: penicillin or streptomycin phosphate or bicillin-5. Inside all sick animals additionally used norsulfazol intramuscularly and vitamins.

The results of the treatment. Treatment 1 experimental group averaged 4-5 days, recovered 48 calves (pneumatic efficiency 96%); in the 2nd experimental group treatment was 6-8 days, recovered 52 telescopecompact averaged for both groups 98,35%

The cost of treatment "Gluconicum in experimental groups was 2 times lower compared to the cost of the antibiotics used in the treatment of animals from the control groups.

P R I m e R 3. In the complex for fattening calves treatment of two groups of calves suffering from bronchopneumonia same age periods, 10 goals each. For the treatment of animal drug use "Glycomics" example 2 a total dose of 20 cm3moreover , the dose for intravenous administration is 15 cm3and the remainder of the dose is 5 cm3intramuscularly with Autocraft.

The results of the treatment. All sick animals recovered, treatment amounted to 4-5 days. The cost of treatment by a preparation "glycomics" compared with the cost of care for animals in the control groups of example 1 was below 2.5 times.

P R I m e R 4. In the complex for fattening calves treatment of animals suffering from bronchopneumonia, age: 20-45 (70 goal); 45-60 days (60 goal); 90 days (50 goal). For treatment instead of antibiotic drug use "Glycomics", containing the following components, wt. Dioxide 0.50 Glucose 30,00 saline Rest of the Drug to the sick animals injected intravenously, once in su the I effectiveness by age groups of experimental animals were respectively 95,6; 95,0; 98,0% of the Cost of treatment in the experimental groups, the drug "Glycomics" compared with the cost of care for animals in the control groups of example 1 was below 2.3 times.

P R I m e R 5. In the complex for fattening calves treatment of animals suffering from bronchopneumonia, age: 20-45 days (82 goal); 45-60 days (56 goal); 90 days (43 goal). Instead of antibiotic therapy, used in combination, for the treatment of animals used in the preparation of "Glycomics", containing the following components, wt. Dioxidine 0,55 Glucose 10,00 saline Else. The drug is administered intravenously, once a day, to recover, at a dose of 10 cm3.

The results of the treatment. Treatment averaged across 3 groups of animals 5-7 days; therapeutic efficacy by age groups of animals, respectively 92,6; 96,4 and 95.3% of the Average cost of treatment of the experimental groups proposed drug 2.7 times lower in comparison with the treatment of antibiotics in the control group of example 1.

P R I m e R 6. In the complex for fattening calves treatment of animals suffering from bronchopneumonia at the age of 30-45 days (100 heads). For treatment of animals instead of antibiotic therapy is 0,00

Saline Rest of the Drug is administered once a day, to recover, in a total dose of 10 cm3moreover , the dose for intravenous administration is 8.0-9.0 cm3and the remainder of the dose of 1.0-2.0 cm3injected animals intramuscularly with Autocraft.

The results of the treatment. The course of treatment is 4-6 days. Therapeutic efficacy of 100% of the Cost of treatment of these animals was 3 times lower in comparison with the use of antibiotics in the control groups in example 1.

P R I m e R 7. In the complex for fattening calves treatment of animals suffering from bronchopneumonia at the age of 20-45 days (76 goal); 45-60 days (57 goals) and 90 days (47 goal). For treatment instead of antibiotic drug use "Glycomics", containing the following components, wt. Dioxidine 0.5 Glucose 5,0 saline Rest of the Drug is administered intramuscularly, once a day, to recover, at a dose of 10 cm3. In severe disease the drug is administered 2 times per day.

The results of the treatment. The course of treatment the average for all experimental groups was 5-7 days. Therapeutic efficacy by age groups of animals, respectively of 92.1; 92,9 and 93.6% of the Cost of the course is different, was 2.7 times lower than after a single dose of the drug and 1.9 times when a double use.

The drug Glycomics" ready for use in veterinary practice for the treatment of acute respiratory diseases of farm animals, in particular bronchopneumonia in calves.

The use of this drug in the treatment of pneumonia in calves can reduce the frequency of treatment of animals, to obtain a high therapeutic effect and reduce to 2-3 times the cost of using chemotherapeutic agents.

The METHOD of TREATMENT of ACUTE RESPIRATORY infections IN YOUNG farm ANIMALS, comprising injecting into the body of the animal until the recovery of the drug-containing chemotherapeutic agent, glucose and a solvent, characterized in that are used for treatment pharmaceutical preparation containing as chemotherapeutic dioxidine, and the solvent is saline in the following ratio, wt.

Dioxidine 0,45 0,55

Glucose 5,00 40,00

Saline Else

which is injected in the animals once a day is

 

Same patents:

The invention relates to new mevalonate with pyrazolopyrimidine ring, processes for their preparation, pharmaceutical compositions containing them and their pharmaceutical use, especially as antihyperlipidemic, hypolipoproteinemia and antiatherosclerotic agents, and to intermediate products useful for their preparation and methods of producing such intermediates

The invention relates to medicine and the new original antihistaminics, anti-allergic drug containing salt Hinkley-3-diphenylcarbinol

The invention relates to an agent against human immunodeficiency virus (HIV)

The invention relates to medicine and can be used to treat diseases caused by dopamine deficiency

FIELD: medicine, phthisiology.

SUBSTANCE: one should lymphotropically introduce the mixture of 5.0 ml 0.25%-novocaine solution and 2.0 ml 1%-dioxidine solution or the mixture of 5.0 ml 0.25%-novocaine solution and 0.5 g cefazoline subcutaneously into jugular cavity and deeply behind xiphoid process, successively 1 point once daily, 5-7 injections/course. After injection the site of injection should be treated either with heparin ointment or ultrasound (1-3 MHz, PPM 0.2 W/sq. cm, for 2 min, through Vaseline oil) followed by evaluating roentgenological dynamics of the process 10-14 d later.

EFFECT: higher efficiency of differential diagnostics.

3 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention describes benzamidine derivatives of the general formula (I): wherein R1 means hydrogen atom, halogen atom, (C1-C6)-alkyl or hydroxyl; R2 means hydrogen atom or halogen atom; R3 means (C1-C6)-alkyl possibly substituted with hydroxy-group, alkoxycarbonyl-(C3-C13)-alkylsulfonyl, carboxy-(C2-C7)-alkylsulfonyl; each among R4 and R5 means hydrogen atom, halogen atom, (C1-C6)-alkyl possibly substituted with halogen atom, (C1-C6)-alkoxy-group, carboxy-group, (C2-C7)-alkoxycarbonyl, carbamoyl, mono-(C2-C7)-alkylcarbamoyl, di-(C3-C13)-alkylcarbamoyl; R6 means heterocycle or similar group; each among R7 and R8 means hydrogen atom, (C1-C6)-alkyl or similar group; n = 0, 1 or 2, or their pharmacologically acceptable salts, esters or amides. Compounds elicit the excellent inhibitory activity with respect to activated factor X in blood coagulation and useful for prophylaxis or treatment of diseases associated with blood coagulation.

EFFECT: improved method for prophylaxis and treatment, valuable medicinal properties of compound.

26 cl, 2 tbl, 253 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention describes diazepane derivative of the general formula (I)

or its pharmaceutically acceptable salt wherein ring B means phenyl; ring A means pyridyl substituted with halogen atom optionally, or phenyl substituted optionally with lower alkyl, lower alkoxy-group or halogen atom; X1 represents -C(=O)-NR2- or -NR2-C(=O)- wherein R2 means hydrogen atom; X2 represents -C(=O)-NR3- or NR3-C(=O)- wherein R3 means hydrogen atom; R represents hydrogen atom or halogen atom; R1 means lower alkyl. Also, invention relates to a pharmaceutical composition and inhibitor of blood coagulation activated factor X that can be used for prophylaxis and treatment of patients suffering with thrombosis or embolism.

EFFECT: valuable medicinal properties of compound.

5 cl, 5 tbl, 6 ex

FIELD: organic chemistry, medicine, oncology, pharmacy.

SUBSTANCE: invention relates to a new pentacyclic compound derivative of taxane represented by the formula:

wherein R1 represents dimethylaminomethyl group or morpholinomethyl group; R2 represents halogen atom or alkoxy-group comprising from 1 to 6 carbon atoms, or its salt eliciting an antitumor effect, and to a medicine agent based on its. Invention provides preparing new derivatives of taxane eliciting the valuable biological effect.

EFFECT: valuable medicinal properties of compound.

13 cl, 1 dwg, 4 tbl, 16 ex

FIELD: organic chemistry, cardiology, pharmacy.

SUBSTANCE: invention describes compounds of the formula (I)

wherein R1, R2, R3 and Ra-Rh have values given in the description. Proposed compounds are useful in prophylaxis and treatment of arrhythmia, in particular, atrial and ventricular arrhythmia, Also, the invention relates to methods for preparing compounds of the formula (I) and intermediate compounds.

EFFECT: valuable medicinal properties of compounds.

41 cl, 1 tbl, 8 ex

FIELD: medicine.

SUBSTANCE: the present innovation deals with preventing hemodynamic complications at restoring circulation in a prolongly ischemized limb, or due to premeditated tourniquet application during operative interference. For this purpose, 5-12 min before the onset of circulatory restoration it is necessary to start intravenous injection of antihistamine and glucocorticosteroid preparations, followed by drop-by-drop infusion of inhibitors of proteolytic enzymes which should be continued after tourniquet removal, as well. The method provides tourniquet shock and tourniquet shock-associated complications along with developing the chance for increasing the duration period of operation.

EFFECT: higher efficiency of prophylaxis.

3 ex

FIELD: organic chemistry, chemical technology, medicine, pharmacy.

SUBSTANCE: invention describes bicyclic N-acylated imidazo-3-amines or imidazo-5-amines salts of the general formula (I): wherein R1 means tert.-butyl, 1,1,3,3-tetramethylbutyl, (C4-C8)-cycloalkyl, phenyl disubstituted with (C1-C4)-alkyl, -CH2Ra wherein Ra means the group -CO(OR') wherein R' means (C1-C8)-alkyl; R2 means hydrogen atom, the group -CORb wherein Rb means (C1-C8)-alkyl or (C3-C8)-cycloalkyl; R3 means (C1-C8)-alkyl, (C3-C8)-cycloalkyl, phenyl, pyridyl, furfuryl or thiophenyl; A means tri-linked fragment of ring of the formula: wherein R6 and R7 mean hydrogen atom or tetra-linked fragment of ring of the following formulae: wherein R4' means hydrogen atom or benzyloxy-group; R5' means hydrogen atom; R6' means hydrogen atom, (C1-C8)-alkyl or nitro- (NO2)-group; R7' means hydrogen atom, (C1-C8)-alkyl, or R6' and R7' mean in common the following fragment of ring: -CRi=CRj-CH=CH- wherein Ri and Rj mean hydrogen atom; R5'' means hydrogen, chlorine atom or (C1-C8)-alkyl; R6'' means hydrogen atom; R7''n means hydrogen atom, amino- (NH2)-group or (C1-C8)-alkyl; R4''', R6''' and R7''' mean hydrogen atom; R8 means (C1-C8)-alkyl or (C3-C8)-cycloalkyl; X means anion of inorganic or organic acid, or their acid-additive compounds. Also, invention relates to a method for their preparing and a pharmaceutical composition based on thereof. These new compounds show affinity to opiate μ-receptor and can be used, in particular, as analgesic agents.

EFFECT: improved preparing method, valuable medicinal properties of compounds and pharmaceutical compositions.

12 cl, 2 dwg, 32 ex

FIELD: organic chemistry, biochemistry, pharmacy.

SUBSTANCE: invention relates to new derivatives of β-carboline of the general formula (I)

showing properties of phosphodiesterase V inhibitor (PDE V). In the general formula (I) R1 means hydrogen atom; n = 0; X is taken among the group consisting of oxygen (O), sulfur (S) atoms and NRD; R2 is taken among the following group: phenyl (that can be optionally substituted with 1-3 RB), 6-membered nitrogen-containing heteroaryl and 5-6-membered heterocycloalkyl comprising 1-2 oxygen atoms and condensed with benzene ring (optionally substituted with 1-3 RB); R4 is taken among the group consisting of hydrogen atom, carboxy-group. (C1-C6)-alkylcarbonyl, di-[C1-C8)-alkyl]-aminoalkoxycarbonyl, di-[(C1-C8)-alkyl]-amino-(C1-C8)-alkylaminocarbonyl; a = a whole number from 0 to 1; Y is taken among the group consisting of -CH2, -C(O); Z is taken among the group consisting of -CH2, -CHOH, and -C(O) under condition that when Z represents -CHOH or -C(O) then X represents -NH; is taken among the group consisting of naphthyl, 5-6-membered heteroaryl comprising 1-3 heteroatoms taken among nitrogen, oxygen and/or sulfur atoms possibly condensed with benzene ring; m = a whole number from 0 to 2; R3 is taken independently among the group consisting of halogen atom, nitro-group, (C1-C8)-alkyl, (C1-C8)-alkoxy-group, trifluorophenyl, phenyl (optionally substituted with 1-3 RB), phenylsulfonyl, naphthyl, (C1-C8)-aralkyl, 5-6-membered heteroaryl comprising 1-3 nitrogen atoms in the ring (optionally substituted with 1-3 RB). Also, invention relates to a pharmaceutical composition, a method for its preparing and methods for inhibition of phosphodiesterase V activity (PDE V), and for increase of the cGMP concentration.

EFFECT: improved preparing method, valuable medicinal and biochemical properties of compounds and composition.

14 cl, 11 sch, 7 tbl, 13 ex

FIELD: organic chemistry, pharmacy.

SUBSTANCE: invention relates to new pharmaceutical compositions comprising bicyclic compound of the formula (I): wherein A means -COOH or their functional derivative; X1 and X2 mean hydrogen or halogen atom; V1 and V2 mean carbon atoms; W1 and W2 mean groups and wherein R4 and R mean hydrogen atom, hydroxy-group; Z means carbon, oxygen, sulfur or nitrogen atom; R1 means saturated or unsaturated bivalent (C1-C10)-aliphatic hydrocarbon residue; R2 means saturated or unsaturated (C1-C10)-aliphatic hydrocarbon residue; R3 means hydrogen atom and glyceride. Also, invention relates to a method for stabilizing compositions and novel bicyclic compounds. Invention provides enhancing stability of pharmaceutical composition based on its dissolving in glyceride.

EFFECT: improved and valuable properties of compositions, improved stabilization of compositions.

42 cl, 8 tbl, 8 ex

FIELD: medicine, neurology, virology.

SUBSTANCE: invention relates to treatment of neurological diseases caused by herpes virus, such as Bell's paralysis, Hunt's disease, herpetic encephalitis accompanying with damage of cerebral nerves. Invention involves using 1,4-dihydropyridine blockers of calcium channels, such as felodipine, nifedipine, nimodipine, nisodipine being taken preferably in combination with herpes virus antagonist. Invention provides repairing damaged cerebral nerves by topical expanding arteriols and recovery of local microcirculation based on specific competitive interaction of definite groups of calcium blockers of 1,4-dihydropyridine type with vasoconstrictor endothelin.

EFFECT: enhanced effectiveness of treatment.

47 cl, 2 dwg, 1 ex

Up!